Experience

Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Anxiety

Validation of the SIS in anxiety
Manuscripts on the development and validation of the Sleep Impact Scale (SIS) in generalised anxiety disorder
PRO strategy in generalized anxiety disorder with functional digestive disorders / irritable bowel syndrome (IBS)

Artery diseases and high cholesterol

Literature review of burden of illness and cardiovascular risk group identification of symptomatic peripheral artery disease
Literature review and payer appraisals in peripheral artery disease
Budget impact and economic evaluation of a statin
Advisory board on arterial occlusive disease
Workshop communicating health economic data of an anticoagulant medication for deep vein thrombosis (DVT)
Development of a treatment satisfaction measure for an injectable low-density lipoprotein (LDL) cholesterol lowering medication
Costs for psychometric validation of the Injection-Treatment Acceptance Questionnaire (I-TAQ) in an independent observational study in hypercholesterolemia
Statistical consultancy to support use of the I-TAQ for a cholesterol-lowering medication
Production of a revised heart model for hypercholesterolaemia incorporating additional comments from country affiliates
Worldwide database analysis of statins and cholesterol levels
Probabilistic analysis of a statin model and advice on a pharmacoeconomic manuscript
Endpoint review for FDA-approved flushing claims in atherosclerosis

Arthritis

Manuscript and analysis on an anti-inflammatory treatment for arthritis
PRO literature review for two different anti-inflammatory drugs for the treatment of arthritis

Ankylosing spondylitis

Interactive cost-effectiveness model for a selective inhibitor treatment used for ankylosing spondylitis
Manuscript cost-effectiveness analysis of a treatment for ankylosing spondylitis in Norway
Workshop and FAQ development in immunology in ankylosing spondylitis
Development of a payer value deck in immunology in ankylosing spondylitis
Competitor review deck in ankylosing spondylitis
Total Brand FAQ deck and Total Brand Workshop in ankylosing spondylitis
Global value dossier and budget impact model for a biosimilar in ankylosing spondylitis
Competitor value story slide deck in ankylosing spondylitis
Core value dossier in ankylosing spondylitis
Global value dossier update for the latest HEOR evidence in ankylosing spondylitis
Development of launch materials in ankylosing spondylitis
HTA strategy in ankylosing spondylitis
GI tolerability endpoint white paper including literature and instrument reviews on ankylosing spondylitis

Axial spondyloarthritis

Payer slide kit in non-radiographic axial spondyloarthritis
Structured literature review and value dossier updates in a biosimilar for axial spondyloarthiritis
Payer value deck for a biosimilar in axial spondyloarthiritis

Juvenile idiopathic arthritis

Workshop and FAQ development in immunology in juvenile idiopathic arthritis
Development of a payer value deck in immunology in juvenile idiopathic arthritis
Frequently asked questions deck in juvenile idiopathic arthritis
Structured literature review and value dossier updates in a biosimilar for juvenile idiopathic arthritis
Payer value deck for a biosimilar in juvenile idiopathic arthritis

Osteoarthritis

Global value dossier and budget impact model for a biosimilar in osteoarthritis
Literature review of PROs and endpoints of pain in osteoarthritis
Literature review to support the use of COA measures in osteoarthritis
Competitive assessment and burden of illness study in osteoarthritis
Review of endpoints for clinical trials in osteoarthritis
Instrument review and assessment strategy in osteoarthritis
Mixed treatment comparison of two treatments for osteoarthritis of the knee
Mode of administration validation study for an electronic diary in back pain for osteoarthritis patients
Development and cognitive debriefing on a patient global response to a treatment measure in osteoarthritis pain
Translation and validation of the revised Hopkins Verbal Learning Test for osteoarthritis
Translation and validation of an osteoarthritis diary
Development of a measure of disease flare in osteoarthritis patients
Patient interviews to capture disease burden and unmet treatment needs in hand osteoarthritis
Mode of administration equivalency and usability testing of COA instruments in osteoarthritis
GI tolerability endpoint white paper including literature and instrument reviews on osteoarthritis
Consulting on PRO analysis and study design of trials in osteoarthritis
Top up literature review of PROs in osteoarthritis
Gap analysis and review of PRO measures in osteoarthritis
Qualitative exit interviews to assess the patient experience of treatment and clinical trial participation among patients with osteoarthritis

Psoriatic arthritis

Payer dossier update in psoriatic arthritis
Support for a manuscript on a network meta-analysis in psoriatic arthritis
Systematic literature review and network analysis in psoriasis and psoriatic arthritis
Targeted literature review in psoriatic arthritis patients with concomitant moderate to severe psoriasis
Workshop and FAQ development in immunology in psoriatic arthritis
Development of a payer value deck in immunology in psoriatic arthritis
Competitor review decks in psoriatic arthritis
Competitor value story slide deck in psoriatic arthritis
Structured literature review and value dossier updates in a biosimilar for psoriatic arthritis
Data checks and DEF amendments in psoriatic arthritis
HTA support regarding psoriatic arthritis submissions in Canada, Spain and the UK
Regulatory support on SMC questions on psoriatic arthritis work
Payer interviews and message testing in psoriatic arthritis
Payer value deck for a biosimilar in psoriatic arthritis
Core value dossier on psoriatic arthritis
Global value dossier update for the latest HEOR evidence in psoriatic arthritis
Development of launch materials in psoriatic arthritis
HTA strategy in psoriatic arthritis
Development and Drug Development Tools (DDT) qualification of a PRO measure to assess the symptoms of psoriatic arthritis

Rheumatoid arthritis

Literature search, data extraction and report on rheumatoid arthritis
Cost-consequences manuscript on rheumatoid arthritis
Generating evidence to support the unmet need in rheumatoid arthritis
Measuring indirect and societal costs of morning stiffness in patients with rheumatoid arthritis
Manuscript on a treatment in rheumatoid arthritis
Review of an economic model to assess utility requirements for a treatment in rheumatoid arthritis
Utility study and economic model in rheumatoid arthritis
Review of European HTA requirements for treatment in rheumatoid arthritis
Adaptation of an economic model on treatment of rheumatoid arthritis for the USA
Value message testing for a biosimilar in rheumatoid arthritis
Objection handler in rheumatoid arthritis
Economic model on a treatment for rheumatoid arthritis
Budget impact model for a biosimilar in rheumatoid arthritis
Competitor review in rheumatoid arthritis
Competitor review of two JAK inhibitors in rheumatoid arthritis
Payer focused value communication on rheumatoid arthritis
Payer value proposition in rheumatoid arthritis
Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
Literature review of unmet need in rheumatoid arthritis
Literature review and recommendations for rheumatoid arthritis
Utility study in rheumatoid arthritis
Competitor value story in rheumatoid arthritis
Competitor value stories for two treatments of rheumatoid arthritis
Manuscript on a budget impact model for a cross-indication biosimilar in conditions including rheumatoid arthritis
Core value dossier, value deck and objection handler in rheumatoid arthritis
Update to an AMCP dossier for a rheumatoid arthritis biosimilar
Global value dossier and budget impact model for a biosimilar in rheumatoid arthritis
Workshop and FAQ development in immunology in rheumatoid arthritis
Development of a payer value deck in immunology in rheumatoid arthritis
Total Brand FAQ deck and Total Brand Workshop in rheumatoid arthritis
Structured literature review and value dossier updates in a biosimilar for rheumatoid arthritis
Review of PROs and preparation and writing of a PRO briefing document for the FDA on the treatment of rheumatoid arthritis
Generation of evidence to support the unmet need in rheumatoid arthritis
Modified Delphi Panel to gain consensus in rheumatology (rheumatoid arthritis)
Update to payer materials in rheumatoid arthritis
Payer value deck for a biosimilar in rheumatoid arthritis
Development of a PRO strategy in rheumatoid arthritis
Qualitative research in rheumatoid arthritis
Poster and manuscript on an indirect comparison of biologic treatments for TNF-IR rheumatoid arthritis patients
Systematic review to explore minimal important differences in PROs for rheumatoid arthritis
Meta-analysis of joint structural deterioration over time in minimally treated rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR)
Mixed treatment comparison of efficacy and safety of an immunosuppressant drug versus a TNF inhibitor drug in rheumatoid arthritis patients with DMARD-IR
Mixed treatment comparison of an oral drug used in the treatment of rheumatoid arthritis
Characterising and predicting treatment response to rheumatoid arthritis biologic therapy
Literature review of unmet need in rheumatoid arthritis
Mixed treatment comparison of a treatment for rheumatoid arthritis populations – DMARD-IR and MTX-naive patients
Q&A and mixed treatment comparison on a treatment for rheumatoid arthritis
Indirect comparison of a monotherapy treatment for rheumatoid arthritis patients with DMARD-IR
Face and content validity testing of a tiredness item in a sample of rheumatoid arthritis patients
Development and Drug Development Tools (DDT) qualification of a PRO measure to assess the symptoms of rheumatoid arthritis
Psychometric evaluation of a PRO in rheumatoid arthritis
Evaluation of fatigue in rheumatoid arthritis using a PRO instrument
Patient interviews on rheumatoid arthritis
Patient interviews to capture disease burden and unmet treatment needs in rheumatoid arthritis
Support in development and analyses of a patient support programme in indications including rheumatoid arthritis
GI tolerability endpoint white paper including literature and instrument reviews on rheumatoid arthritis
Top up literature review of PROs in rheumatoid arthritis
Development and Drug Development Tools (DDT) qualification of a PRO measure to assess the symptoms of rheumatoid arthritis

Asthma

Systematic literature review on treatment patterns and burden of illness in asthma
Literature review, analysis and communications for asthma costs
Literature review of critical handling errors in asthma
Real-world evidence literature review in asthma
Landscape analysis in asthma and model assessment to support positioning paper
Structured literature reviews for paediatric wheeze detection
Rapid structured literature review of nebulisation inhalation efficiency in paediatric asthma and other respiratory conditions
Competitor literature review for real world evidence in asthma
Advisory board meeting on a literature review in asthma
Simple cost-utility model and targeted literature review for the treatment of asthma
Budget impact model and manuscript on asthma
Consultancy on exploratory economic modelling in severe asthma
Update to the pilot inference model for an inhaler used in the treatment of asthma
Health economic model in asthma
Economic model of asthma therapies for NICE
Economic model of combination asthma therapies for NICE
Resource use costing in asthma and communicating product value to a local payer audience
Global value dossier update on paediatric asthma
Global value dossier update and e-v@luate upload for an asthma device
Development of a mini global value dossier for an asthma device
e-v@luate platform development for paediatric asthma
Updates to critical handling error manuscript in asthma
Development of a manuscript in mild persistent asthma in specific geographies
Update to a critical handling errors manuscript in asthma
Preparation of a submission dossier for NICE on paediatric inhaled corticosteroid (ICS) drug use in asthma
Several conference posters on asthma, an asthma model, and economic analysis for the treatment of asthma
Advisory panel in asthma
Regulatory strategy consultancy in asthma
Consultancy on obtaining FDA approval of a treatment satisfaction claim for a new asthma treatment
Confirmation of an endpoint model for patients with asthma currently receiving treatment
PRO consulting on an asthma program for labelling
Cognitive debriefing to confirm the face and content validity of secondary endpoint questions in asthma
Database analysis and manuscript assessing death rate and hospitalisation rate in asthmatics
Development of a conceptual model and conceptual framework for the measurement of asthma control
Testing of a conceptual model of asthma in adolescents
Development of a symptom-based PRO instrument for adults and adolescents with asthma
Exit interviews to provide additional evidence of content validity for a quantitative study in asthma
Exit interviews on a connected inhaler system for asthma
Cognitive debriefing interviews in asthma
Validation of the Asthma Control Questionnaire (ACQ) using trial data
Manuscript on the psychometric validation of the ACQ report
Analyses of the ACQ
Conference poster reporting a ROC analysis performed to define cutpoints for the ACQ
Development of a questionnaire to assess control in children with paediatric asthma
Longitudinal validation of the Childhood Asthma Control Test (C-ACT)
Analysis and abstract on the longitudinal validation of the C-ACT
Validity assessment of the C-ACT in Japanese children
Validity assessment of the C-ACT in Hong Kong Chinese children
Complementary analyses on the C-ACT
Minimal clinically important differences for the C-ACT and symptom-free days/rescue medication–free days in paediatric asthma populations
Consulting on the linguistic validation of the C-ACT
Translation of the C-ACT
Equivalency testing of the modified Childhood Asthma Control Test (C-ACT) in children with mild to severe asthma
Cognitive debriefing of the Asthma Symptom and Control Diary (ASCD)
Linguistic validation of the Inhaled Corticosteroid Questionnaire (ICQ) into US English
Exit interviews and evaluation of the psychometric properties of the Asthma Daily Symptom Diary (ADSD) in severe asthma
Quantitative study to confirm the content validity of the ADSD
Development of a preference-based instrument specific to asthma

Asthma COPD overlap syndrome

Slide deck and manuscript in Asthma COPD Overlap Syndrome (ACOS)
Structured literature review on ACOS
Adequacy of COPD PROs for patients with ACOS

Atopic keratoconjunctivitis

Evaluation of focus groups, item generation, cognitive debriefing and analysis plan in atopic keratoconjunctivitis
Poster communication on atopic keratoconjunctivitis
Manuscript in atopic keratoconjunctivitis

Atrial fibrillation

Payer digital value communication testing in stroke prevention in patients with atrial fibrillation (SPAF)
Analysis of atrial fibrillation in the UK
Qualitative research on PROs in atrial fibrillation
Development of PRO instrument modules and validation research in atrial fibrillation
Manuscript on the development of a symptoms questionnaire in atrial fibrillation
Decentralised framework for real life data generation in stroke prevention in atrial fibrillation (SPAF)
Reporting of development work in atrial fibrillation
Indirect comparison of two drugs used in the prevention of thromboembolic events due to atrial fibrillation
Analysis of the Anti-Clot Treatment Scale (ACTS), Treatment Satisfaction Questionnaire for Medication (TSQM) and healthcare resource utilization in a clinical trial in atrial fibrillation
Manuscript development on the ACTS/TSQM data
Manuscript support for statistical results in an observational study measuring outcomes in atrial fibrillation
Measurement of resource use, satisfaction, productivity and HRQoL in atrial fibrillation
Translation and validation of the ACTS and TSQM in atrial fibrillation in Japan

Atypical Hemolytic Uremic Syndrome

Qualitative literature and instrument review in atypical Hemolytic Uremic Syndrome (aHUS)

Autism

Equivalency testing of an eCOA version of the Vineland Adaptive Behavior Scales II (VABS-II) for use in autism spectrum disorder

Barth syndrome

Concept elicitation interviews in Barth syndrome patients
Concept selection meeting for a PRO in Barth syndrome
Cognitive debriefing for Barth syndrome PROs
Qualitative concept elicitation and case studies documenting the disease progression of Barth Syndrome

Biliary tract cancer

Structured literature review in biliary tract cancer

Biosimilars

Endocrinology

Payer value slide deck for a biosimilar in diabetes
Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus
Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar

Immunology

Payer value slides for immunology biosimilars
Frequently asked questions to support the introduction of a new biosimilar in immunology
Frequently asked questions for biosimilar policy in immunology
Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
Budget impact model for a biosimilar
Literature review and update to budget impact model in an immunology biosimilar
Updates to a US budget impact model for an immunology biosimilar
Update to an AMCP dossier for an immunology biosimilar
Originator vs. biosimilar value proposition update in immunology
Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar
Structured literature review and value dossier updates in a biosimilar for axial spondyloarthiritis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, paediatric Crohn’s disease, paediatric plaque psoriasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis and uveitis
Budget impact model on a biosimilar in multiple immunology indications

Musculoskeletal diseases

Value message testing for a biosimilar in rheumatoid arthritis
Budget impact model for a biosimilar in autoimmune disease

Oncology

Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
Development of a cost-calculator for a biosimilar for breast and gastric cancer
One-pager communication in a breast cancer biosimilar
Payer value deck update for a breast cancer biosimilar
Response to payer questions update for a breast cancer biosimilar
Budget impact model for a biosimilar in HER2 breast cancer
Budget impact model on an oncology biosimilar
Budget impact model for a biosimilar in multiple oncology indications

Women’s health

Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
Pricing updates in Europe for a biosimilar hormone treatment for female infertility

Other

Global value and reimbursement dossier for a biosimilar in autoimmune disease
Biosimilar payer communications in dermatology, gastroenterology and immunology
Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease (IBD), osteoarthritis, psoriasis and rheumatoid arthritis
Manuscript on a budget impact model for a biosimilar in haematology and rheumatology

Bipolar disorder

Systematic literature review and manuscript on the burden of illness in bipolar disorder
Psychometric validation of the Sheehan Disability Scale in bipolar disorder
Support network study to improve compliance in a psychotropic medication used in bipolar disorder
FDA PRO dossier on bipolar depression
Development of an endpoint model, training and recommendations for endpoint support in bipolar disorder
Composition of a PASS report on bipolar disorder, including a review of local physician monitoring guidelines
Validation of the Caregiver Strain Questionnaire in paediatric bipolar disease

Bladder cancer

Burden of disease deck in bladder cancer
Payer value deck in bladder cancer
Frequently asked questions in bladder cancer
Payer implementation guide in bladder cancer
Burden of disease deck, payer value dossier deck and frequently asked questions deck in 2nd line bladder cancer
Burden of disease deck in non-muscle invasive bladder cancer
Payer value deck update in 2nd line bladder cancer
Standardization of economic models in bladder cancer
Qualitative research in bladder cancer
Clinical trial analyses to support health-related quality of life in bladder cancer
‘Fit for purpose’ tools review in bladder cancer
Development of a new PRO measure in bladder cancer
AMNOG analyses to support health-related quality of life in bladder cancer

Brain metastases

Development and validation of a PRO measure in brain metastases
Development and validation of a questionnaire to assess brain metastases
Linguistic validation of a brain metastases assessment

Brain tumours

Health Economics and Translational Advisory Board on paediatric brain tumours
Support in personalised medicine health economics on brain tumours

Breast cancer

Global value dossier for treatment in breast cancer
Data collection of costs associated with breast cancer care
Manuscript on the German model for a hormonal drug used in the treatment of breast cancer
Development of two budget impact models in breast cancer with population data by city
Two budget impact models for Italy for an injectable chemotherapy drug for breast cancer
Budget impact model in breast cancer for France
Development of a cost-calculator for a biosimilar for breast cancer
Payer value deck in breast cancer
Payer value deck update for a breast cancer biosimilar
Burden of disease deck in breast cancer
Response to payer questions in breast cancer
Response to payer questions update for a breast cancer biosimilar
Burden of disease deck and frequently asked questions deck in breast cancer biosimilars
One-pager communication in a breast cancer biosimilar
Productivity and QoL study in breast cancer
Literature review and consultancy on breast cancer
e-v@luate platforms in breast cancer
Market access training and workshop on breast cancer
Primary research of fixed dose combinations pricing in breast cancer

HER2 positive breast cancer

Literature review of productivity data in HER2 positive breast cancer
Budget impact model for a biosimilar in HER2 breast cancer

Advanced breast cancer

Development of a perceived tolerability questionnaire in first line treatment of advanced breast cancer
Strategy for an injectable chemotherapy drug for advanced breast cancer and submission to NICE/SMC
Budget impact model and analysis for an injectable chemotherapy drug for advanced breast cancer in 5 EU countries
Economic evaluation of a therapy for postmenopausal women with advanced breast cancer (with the perspective of 3rd party national and local payers in the UK)
Development and population of an economic model in advanced breast cancer
Conference poster on a cost utility analysis of two treatments for advanced breast cancer
Conference poster on the economic evaluation of a therapy for postmenopausal women with advanced breast cancer
Phase IV non-interventional prospective observational study comparing patient reported outcomes in advanced breast cancer
PRO label review manuscript development in advanced/metastatic breast cancer

Metastatic breast cancer

Value dossier and e-v@luate platform in metastatic breast cancer
Scientific communication of cost-effectiveness analysis in metastatic breast cancer
PRO knowledge base instruments and methods library for metastatic breast cancer
Update to a Health Impact Projection (HIP) model in metastatic triple negative breast cancer

Triple negative breast cancer

Global value dossier and upload to e-v@luate platform in triple negative breast cancer
Data analyses on a multi-indication budget impact model and cost utility model in triple negative breast cancer
Payer value tool in triple negative breast cancer (TNBC)
Standalone budget impact models in triple negative breast cancer
Update to a Health Impact Projection (HIP) model in neo-adjuvant triple negative breast cancer

Bronchitis

Development of a cough and sputum questionnaire in chronic bronchitis in 7 languages
Validation of a cough and sputum questionnaire in chronic bronchitis
Development and validation of a patient diary for evaluating acute exacerbation of chronic bronchitis
Conducting European focus group sessions for acute exacerbation of chronic bronchitis
Validation of a patient diary for evaluating acute exacerbation of chronic bronchitis (AECB)

Cancer-related pain, fatigue and side effects

Cancer-related pain and fatigue

Initial consultation to design a study in order to generate health utilities values associated with different levels of cancer-related pain
Utility study in breakthrough cancer pain
Update of report for utility elicitation in breakthrough cancer pain
Abstract, manuscript and budget impact model on breakthrough cancer pain
Training in pilot budget impact model for a treatment for patients with breakthrough cancer pain
SMC submission in breakthrough cancer pain
Development of a breakthrough cancer pain submission to the All Wales Medicines Strategy Group (AWMSG)
Attendance at an AWMSG meeting with regards to strategic consultancy in breakthrough cancer pain
Expert interviews and amendment project to heath economic model for a treatment for breakthrough cancer pain
Economic evaluation of a treatment for breakthrough cancer pain in Canada
Budget impact tool for a treatment for patients with breakthrough cancer pain in the UK
Consulting support and development of a briefing document to support fatigue symptom claims in cancer pain
Recommendation of a measure of chronic cancer pain
Assessment of a pain communication tool for advanced cancer patients: a cross-sectional survey
Qualitative research for the Cancer-Related Fatigue Consortium
Phase II cognitive interviews on Patient-Reported Outcomes of Fatigue – Cancer (PROOF-C)
Cancer-related fatigue consortium: qualitative research in the experience of fatigue among cancer patients
Qualitative research on the experience of fatigue among cancer patients
PRO development, abstracts and posters on cancer-related fatigue

Cancer-related anaemia

Linking a cost utility assessment model with a budget impact model for treatment for anaemia in cancer
NICE consultancy for a treatment for chemotherapy-induced anaemia
Statistical pharmacoeconomic analysis of patient level data for a treatment for anaemia following chemotherapy
Phase II cognitive interviews and regulatory support in inflammatory anaemia in cancer
Evaluation of the PRO landscape using a systematic literature review on chemo-induced anaemia in oncology

Other cancer-related side effects

Value dossier on a drug used to treat febrile neutropenia
Plan, execute and follow up a Train-the-Trainer meeting on chemotherapy-induced febrile neutropenia
Development of a PRO measure in muscle wasting (cancer cachexia) in prostate cancer, sarcopenia, gastric cancer and colorectal cancer
Debriefing of the cancer associated fibroblasts (CaF) PRO
SMC re-submission and economic analysis for a treatment for anthracycline extravasation
Case control study of costs associated with a treatment for oral mucositis in transplant patients
Literature review and recommendations on PROs for peripheral neuropathy due to chemotherapy in cancer patients
Review of PRO instruments for use in uveal melanoma and biliary tract cancer

Cataracts

Etiology and meta-analysis of posterior cacular opacification comparing two lens types
Meta-analysis of phacoemulsification, extracapsular cataract extraction (ECCE) and manual small incision cataract surgery (MSICS) in Asia
Formal recommendations on a regulatory briefing document for intraocular cataract lenses
Development of a PRO questionnaire to assess implantation of an intraocular lens in cataract patients
Cognitive interviews for the development of a PRO to assess intraocular lenses in cataract patients
Support on the intraocular lenses Expert Focus Group
Quality of life study in cataracts